Celldex Therapeutics, Inc.

Jasper Therapeutics’ c-Kit inhibitor, briquilimab, demonstrated efficacy in a Phase II trial in patients with chronic spontaneous urticaria (CSU) that appears on par with rival Celldex’s barzolvolimab

At its R&D day yesterday, InflaRx N.V. talked up its oral complement C5a inhibitor INF904 as a “pipeline-in-a-product”, but this is a bold claim to make for a molecule that has barely entered the cl

Incyte Corporation sees potential in Escient Pharmaceuticals Inc. ’s MRGPR X2 and X4 antagonists to augment ongoing programs in its pipeline and to begin generating revenue at about the same time th

The market for biopharmaceutical company initial public offerings and follow-on public offerings has become more friendly this year, but some firms still are circumventing the public offering route an